litlas
ログインアカウント作成

Wu‐Chou Su

1990–2025 年に発表

別表記
Wu-Chou Su
131
論文数
27,214
被引用数
72
h 指数
124
i10 指数

被引用数

Wu‐Chou Su の年別被引用数1990 年: 被引用 2 件1991 年: 被引用 15 件1992 年: 被引用 13 件1993 年: 被引用 24 件1994 年: 被引用 12 件1995 年: 被引用 11 件1996 年: 被引用 17 件1997 年: 被引用 35 件1998 年: 被引用 45 件1999 年: 被引用 56 件2000 年: 被引用 51 件2001 年: 被引用 38 件2002 年: 被引用 35 件2003 年: 被引用 29 件2004 年: 被引用 19 件2005 年: 被引用 23 件2006 年: 被引用 32 件2007 年: 被引用 26 件2008 年: 被引用 31 件2009 年: 被引用 16 件2010 年: 被引用 18 件2011 年: 被引用 39 件2012 年: 被引用 52 件2013 年: 被引用 155 件2014 年: 被引用 176 件2015 年: 被引用 277 件2016 年: 被引用 299 件2017 年: 被引用 256 件2018 年: 被引用 299 件2019 年: 被引用 1,171 件2020 年: 被引用 1,154 件2021 年: 被引用 1,223 件2022 年: 被引用 1,001 件2023 年: 被引用 821 件2024 年: 被引用 1,338 件2025 年: 被引用 729 件2026 年: 被引用 18 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,685 件、この内訳の 22.1%中国: 引用元論文 2,009 件、この内訳の 16.5%日本: 引用元論文 685 件、この内訳の 5.6%イタリア: 引用元論文 590 件、この内訳の 4.9%イギリス: 引用元論文 541 件、この内訳の 4.5%ドイツ: 引用元論文 451 件、この内訳の 3.7%フランス: 引用元論文 439 件、この内訳の 3.6%スペイン: 引用元論文 424 件、この内訳の 3.5%韓国: 引用元論文 424 件、この内訳の 3.5%台湾: 引用元論文 413 件、この内訳の 3.4%カナダ: 引用元論文 368 件、この内訳の 3%オランダ: 引用元論文 262 件、この内訳の 2.2%
0%22.1%その他 23.5%

機関

分野

  • Medicine70%
  • Biochemistry, Genetics and Molecular Biology21.8%
  • Immunology and Microbiology2.7%
  • Chemistry1%
  • Materials Science0.9%
  • Engineering0.8%
  • その他2.8%

トピック

  • Lung Cancer Treatments and Mutations16%
  • Lung Cancer Research Studies6.2%
  • Cancer Immunotherapy and Biomarkers5.7%
  • Lung Cancer Diagnosis and Treatment4.7%
  • Cancer Genomics and Diagnostics3.8%
  • HER2/EGFR in Cancer Research2.5%
  • その他61.1%

共著者

全論文

検索で開く
  1. Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer

    著者: Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata, Isamu Okamoto, Caicun Zhou, Byoung Chul Cho, Ying Cheng, Eun Kyung Cho, Pei Jye Voon, David Planchard, Wu‐Chou Su, Jhanelle E. Gray, Siow Ming Lee, Rachel Hodge, Marcelo Marotti, Yuri Rukazenkov, Suresh S. Ramalingam - New England Journal of Medicine 2017 被引用: 5,269

  2. Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC

    著者: Masahiro Tsuboi, Roy S. Herbst, Thomas John, Terufumi Kato, Margarita Majem, Christian Grohé, Jie Wang, Jonathan W. Goldman, Shun Lü, Wu‐Chou Su, Filippo de Marinis, Frances A. Shepherd, Ki Hyeong Lee, Nhieu Thi Le, Arunee Dechaphunkul, Dariusz M. Kowalski, Lynne Poole, Ana Bolanos, Yuri Rukazenkov, Yi‐Long Wu - New England Journal of Medicine 2023 被引用: 612

  3. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

    著者: Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, С. В. Орлов, Chun‐Ming Tsai, Michael Boyer, Wu‐Chou Su, Jaafar Bennouna, Terufumi Kato, В. А. Горбунова, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schüler - Journal of Clinical Oncology 2013 被引用: 3,198

  4. AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

    著者: Pasi A. Jänne, James Chih‐Hsin Yang, Dong‐Wan Kim, David Planchard, Yuichiro Ohe, Suresh S. Ramalingam, Myung‐Ju Ahn, Sang-We Kim, Wu‐Chou Su, Leora Horn, Daniel Haggstrom, Enriqueta Felip, Joo-Hang Kim, Paul Frewer, Mireille Cantarini, Kathryn H. Brown, Paul A. Dickinson, Serban Ghiorghiu, Malcolm Ranson - New England Journal of Medicine 2015 被引用: 2,111

  5. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR -Mutated Non–Small Cell Lung Cancer

    著者: Pasi A. Jänne, Christina Baik, Wu-Chou Su, Melissa L. Johnson, Hidetoshi Hayashi, Makoto Nishio, Dong-Wan Kim, Marianna Koczywas, Kathryn A. Gold, Conor E. Steuer, Haruyasu Murakami, James Chih-Hsin Yang, Sang-We Kim, Michele Vigliotti, Rong Shi, Zhenhao Qi, Yang Qiu, Lihui Zhao, David Sternberg, Channing Yu, Helena A. Yu - Cancer Discovery 2021 被引用: 287

  6. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON

    著者: Ryan J. Hartmaier, Aleksandra Markovets, Myung‐Ju Ahn, Lecia V. Sequist, Ji‐Youn Han, Byoung Chul Cho, Helena A. Yu, Sang‐We Kim, James Chih‐Hsin Yang, Jong Seok Lee, Wu‐Chou Su, Dariusz M. Kowalski, С. В. Орлов, Song Ren, Paul Frewer, Xiaoling Ou, Darren A.E. Cross, Nisha Kurian, Mireille Cantarini, Pasi A. Jänne - Cancer Discovery 2022 被引用: 154

  7. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

    著者: Roy S. Herbst, Edward B. Garon, Dong‐Wan Kim, Byoung Chul Cho, Radj Gervais, José Luis Perez‐Gracia, Ji‐Youn Han, Margarita Majem, Martin Förster, I. Monnet, Silvia Novello, Matthew A. Gubens, Michael Boyer, Wu‐Chou Su, Ayman Samkari, Erin Jensen, Julie Kobie, Bilal Piperdi, Paul Baas - Journal of Thoracic Oncology 2021 被引用: 312

  8. Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

    著者: Vassiliki A. Papadimitrakopoulou, Tony Mok, Ji‐Youn Han, Myung‐Ju Ahn, Angelo Delmonte, Suresh S. Ramalingam, Seung‐Whan Kim, Frances A. Shepherd, Janessa Laskin, Yong He, Hiroaki Akamatsu, Willemijn S.M.E. Theelen, Wu‐Chou Su, Thomas John, Martin Sebastian, Helen Mann, Michele Miranda, Gianluca Laus, Yuri Rukazenkov, Yi‐Long Wu - Annals of Oncology 2020 被引用: 276

  9. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

    著者: Lecia V. Sequist, Ji‐Youn Han, Myung‐Ju Ahn, Byoung Chul Cho, Helena A. Yu, Sang-We Kim, James Chih‐Hsin Yang, Jong Seok Lee, Wu‐Chou Su, Dariusz M. Kowalski, Sergey Orlov, Mireille Cantarini, Remy B. Verheijen, Anders Mellemgaard, Lone H. Ottesen, Paul Frewer, Xiaoling Ou, Geoffrey R. Oxnard - The Lancet Oncology 2020 被引用: 413

  10. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

    著者: D. Ross Camidge, Fabrice Barlési, Jonathan W. Goldman, Daniel Morgensztern, Rebecca S. Heist, Everett E. Vokes, Alexander I. Spira, Eric Angevin, Wu‐Chou Su, David S. Hong, John H. Strickler, Monica Motwani, Martin Dunbar, Apurvasena Parikh, Elysa Noon, Vincent Blot, Jun Wu, Karen Kelly - Journal of Clinical Oncology 2022 被引用: 104

  11. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

    著者: James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler, Martin Sebastian, Sanjay Popat, Nobuyuki Yamamoto, Caicun Zhou, Cheng-Ping Hu, Kenneth J. O’Byrne, Jifeng Feng, Shun Lü, Yunchao Huang, Sarayut Lucien Geater, Kye Young Lee, Chun-Ming Tsai, В. А. Горбунова, Vera Hirsh, Jaafar Bennouna, С. В. Орлов, Tony Mok, Michael Boyer, Wu‐Chou Su, Ki Hyeong Lee, Terufumi Kato, Dan Massey, Mehdi Shahidi, Victoria Zazulina, Lecia V. Sequist - The Lancet Oncology 2015 被引用: 1,580

  12. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer

    著者: Yi‐Long Wu, Li Zhang, Dong‐Wan Kim, Xiaoqing Liu, Ki Hyeong Lee, James Chih‐Hsin Yang, Myung‐Ju Ahn, Johan Vansteenkiste, Wu‐Chou Su, Enriqueta Felip, Vincent Chia, Sabine Glaser, Philippe Pultar, Sylvia Zhao, Bin Peng, Mikhail Akimov, Daniel S.W. Tan - Journal of Clinical Oncology 2018 被引用: 331

  13. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

    著者: Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, Julien Mazières, Johan Vansteenkiste, H. Léna, Jesus Corral Jaime, Jhanelle E Gray, John D. Powderly, C. Chouaïd, Paolo Bidoli, Paul Wheatley‐Price, Keunchil Park, Ross A. Soo, Yifan Huang, Catherine Wadsworth, Phillip A. Dennis, Naiyer A. Rizvi, Luis Paz-Ares Rodríguez, Silvia Novello, Sandrine Hiret, Peter Schmid, Eckart Laack, Raffaele Califano, Makoto Maemondo, Sang‐We Kim, Jamie E. Chaft, David Vicente Baz, Thierry Berghmans, Dong‐Wan Kim, Veerle Surmont, Martin Reck, Ji‐Youn Han, Esther Holgado Martin, Cristóbal Belda-Iniesta, Yuichiro Oe, Antonio Chella, Akhil Chopra, G. Robinet, Héctor Soto Parrà, Michael J. Thomas, Parneet Cheema, Nobuyuki Katakami, Wu‐Chou Su, Young‐Chul Kim, Juergen Wolf, Jong-Seok Lee, Hideo Saka, Michele Stanislaw Milella, Inmaculada Ramos García, Anne Sibille, Takashi Yokoi, Eun Joo Kang, Shinji Atagi, E. Spaeth-Schwalbe, Makoto Nishio, Fumio Imamura, Nashat Gabrail, Rémi Veillon, Sofie Derijcke, Tadashi Maeda, Dylan M. Zylla, Kendra Kubiak, Armando Santoro, Ma. Noemi Uy, Sarayut Lucien Geater, Antoîne Italiano, Dariusz M. Kowalski, Fabrice Barlési, Yuh‐Min Chen, David R. Spigel, Busyamas Chewaskulyong, Ramón García Gómez, Rosa Álvarez, Chih-Hsin Yang, Te‐Chun Hsia, Fabrice Denis, Hiroshi Sakai, Mark Vincent, Kōichi Goto, Joaquim Bosch‐Barrera, Glen J. Weiss, Jean-Luc Canon, Christian W. Scholz, Massimo Aglietta, Hirotsugu Kemmotsu, Koichi Azuma, Penelope A. Bradbury, Ronald Feld, Abraham Chachoua, Jacek Jassem, Rosalyn A. Juergens, Ramon Palmero Sanchez, Albert Malcolm, Nandagopal Vrindavanam, Kaoru Kubota, Cornelius F. Waller, David Waterhouse, Bruno Coudert, Z. Mark ほか 52 名 - The Lancet Oncology 2018 被引用: 576

  14. Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study

    著者: Gee‐Chen Chang, Chao‐Hua Chiu, Chong‐Jen Yu, Yeun‐Chung Chang, Ya‐Hsuan Chang, Kuo-Hsuan Hsu, Yu‐Chung Wu, Chih-Yi Chen, Hsian-He Hsu, Ming‐Ting Wu, Cheng‐Ta Yang, Inn‐Wen Chong, Yu‐Ching Lin, Te‐Chun Hsia, Meng‐Chih Lin, Wu‐Chou Su, Chih‐Bin Lin, Kang‐Yun Lee, Yu‐Feng Wei, Gong‐Yau Lan, Wing P. Chan, Kao-Lun Wang, Mei‐Han Wu, Hao‐Hung Tsai, Chih‐Feng Chian, Ruay-Sheng Lai, Jin‐Yuan Shih, Chi-Liang Wang, Jui‐Sheng Hsu, Kun‐Chieh Chen, Chun-Ku Chen, Jiun‐Yi Hsia, Chung‐Kan Peng, En‐Kuei Tang, Chia‐Lin Hsu, Teh‐Ying Chou, Wei‐Chih Shen, Ying‐Huang Tsai, Chun‐Ming Tsai, Yuh‐Min Chen, Yu‐Chin Lee, Hsuan‐Yu Chen, Sung‐Liang Yu, Chien-Jen Chen, Yung‐Liang Wan, Chao A. Hsiung, Pan‐Chyr Yang, Chang‐Chuan Chan, Si‐Wa Chan, I‐Shou Chang, Jer‐Hwa Chang, K. S. Clifford Chao, Chi‐Jen Chen, Huei‐Wen Chen, Chun‐Ju Chiang, Hung‐Yi Chiou, Mei‐Chun Chou, Chi‐Li Chung, Ta‐Jung Chung, Yue Leon Guo, Chin‐Fu Hsiao, Chien‐Sheng Huang, Sheung‐Fat Ko, Mei–Hsuan Lee, Yao‐Jen Li, Yu-San Liao, Yueh‐Hsun Lu, Hsin‐You Ou, Pingan Wu, Hwai‐I Yang, Shi‐Yi Yang, Szu‐Chun Yang - The Lancet Respiratory Medicine 2023 被引用: 158

  15. Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study

    著者: Roy S. Herbst, Edward B. Garon, Dong‐Wan Kim, Byoung Chul Cho, José Luis Perez‐Gracia, Ji‐Youn Han, Catherine Dubos Arvis, Margarita Majem, Martin Förster, I. Monnet, Silvia Novello, Zsuzsanna Szalai, Matthew A. Gubens, Wu‐Chou Su, Giovanni Luca Ceresoli, Ayman Samkari, Erin Jensen, Gregory M. Lubiniecki, Paul Baas - Journal of Clinical Oncology 2020 被引用: 281

  16. Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component

    著者: James Chih‐Hsin Yang, Myung‐Ju Ahn, Dong‐Wan Kim, Suresh S. Ramalingam, Lecia V. Sequist, Wu‐Chou Su, Sang-We Kim, Joo-Hang Kim, David Planchard, Enriqueta Felip, Fiona Blackhall, Daniel Haggstrom, Kiyotaka Yoh, Silvia Novello, Kathryn A. Gold, Tomonori Hirashima, Chia‐Chi Lin, Helen Mann, Mireille Cantarini, Serban Ghiorghiu, Pasi A. Jänne - Journal of Clinical Oncology 2017 被引用: 572

  17. Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

    著者: Mengzhao Wang, James Chih-Hsin Yang, Paul L. Mitchell, Jian Fang, D. Ross Camidge, Weiqi Nian, Chao-Hua Chiu, Jianying Zhou, Yanqiu Zhao, Wu-Chou Su, Tsung-Ying Yang, Viola W. Zhu, Michael Millward, Yun Fan, Wen-Tsung Huang, Ying Cheng, Liyan Jiang, Daniel Brungs, Lyudmila Bazhenova, Chee Khoon Lee, Bo Gao, Yan Xu, Wei-Hsun Hsu, Li Zheng, Pasi A. Jänne - Cancer Discovery 2022 被引用: 119

  18. 1314MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

    著者: Luis Paz‐Ares, M-J. Ahn, Aaron Lisberg, Satoru Kitazono, B.C. Cho, George R. Blumenschein, Elaine Shum, E. Pons-Tostivint, Yasushi Goto, Kiyotaka Yoh, Rebecca S. Heist, P. Baas, David Planchard, M. Pérol, Enriqueta Felip, Wu‐Chou Su, H. Zebger-Gong, Lei Lan, C. Liu, Jacob Sands - Annals of Oncology 2023 被引用: 50

  19. TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).

    著者: Yasushi Goto, Wu‐Chou Su, Benjamin Levy, Olivier Rixe, Tsung‐Ying Yang, Anthony W. Tolcher, Yanyan Lou, Yoshitaka Zenke, Panos Savvides, Enriqueta Felip, Manuel Dómine, Konstantinos Leventakos, Mariano Provencio, Atsushi Horiike, Edward Pan, Daisy Lin, Jessie Gu, Priyanka Basak, Michael Chisamore, Luis Paz‐Ares - Journal of Clinical Oncology 2023 被引用: 52

  20. Iron oxide@chlorophyll clustered nanoparticles eliminate bladder cancer by photodynamic immunotherapy-initiated ferroptosis and immunostimulation

    著者: Yu‐Cheng Chin, Li‐Xing Yang, Fei‐Ting Hsu, Che-Wei Hsu, Te-Wei Chang, Hsi-Ying Chen, Linda Chen, Zi Chun Chia, Chun-Hua Hung, Wu‐Chou Su, Yi‐Chun Chiu, Chih‐Chia Huang, Mei‐Yi Liao - Journal of Nanobiotechnology 2022 被引用: 91

  21. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

    著者: Vincent A. Miller, Vera Hirsh, Jacques Cadranel, Yuh-Min Chen, Keunchil Park, Sang-We Kim, Caicun Zhou, Wu‐Chou Su, Mengzhao Wang, Yan Sun, Dae Seog Heo, Lucio Crinò, Eng-Huat Tan, Tsu-Yi Chao, Mehdi Shahidi, Xiuyu Julie Cong, Robert M. Lorence, James Chih‐Hsin Yang - The Lancet Oncology 2012 被引用: 953

  22. Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors

    著者: Antoine Hollebecque, Hyun C. Chung, Maria J. de Miguel, Antoine Italiano, Jean-Pascal Machiels, Chia-Chi Lin, Neesha C. Dhani, Marc Peeters, Victor Moreno, Wu-Chou Su, Kay Hoong Chow, Violeta R. Galvao, Michelle Carlsen, Danni Yu, Anna M. Szpurka, Yumin Zhao, Shelly L. Schmidt, Leena Gandhi, Xiaojian Xu, Yung-Jue Bang - Clinical Cancer Research 2021 被引用: 62

  23. Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

    著者: Jacob Sands, Myung‐Ju Ahn, Aaron Lisberg, Byoung Chul Cho, George Blumenschein, Elaine Shum, Elvire Pons‐Tostivint, Yasushi Goto, Kiyotaka Yoh, Rebecca S. Heist, Junichi Shimizu, Jong Seok Lee, Paul Baas, David Planchard, M. Pérol, Enriqueta Felip, Wu‐Chou Su, Hong Zebger‐Gong, Lan Lan, Chelsea Liu, Paul Howarth, Rachel Chiaverelli, Luis Paz‐Ares - Journal of Clinical Oncology 2025 被引用: 98

  24. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment

    著者: I‐Ying Kuo, You-En Yang, Pei‐Shan Yang, Yu‐Jou Tsai, Hong‐Tai Tzeng, Hung‐Chi Cheng, Wan‐Ting Kuo, Wu‐Chou Su, Chih‐Peng Chang, Yi‐Ching Wang - Theranostics 2021 被引用: 75